Sector News

Pfizer boosts Paxlovid manufacturing capacity as Merck’s rival COVID pill hits surprise efficacy setback

December 5, 2021
Life sciences

The efficacy data for Pfizer’s oral COVID-19 drug now look so appealing that the Big Pharma company is boosting manufacturing capacity even before an expected emergency use authorization from the FDA.

Pfizer now expects to make 80 million courses of COVID drug Paxlovid by the end of 2022, Pfizer CEO Albert Bourla, Ph.D., told CNBC during a Monday interview. The company previously said it plans to have capacity to make 50 million courses.

The revelation came after Merck reported the risk reduction in hospitalization and death from its Ridgeback Therapeutics-partnered COVID antiviral, molnupiravir, fell from 50% to 30% in the final analysis. The updated result fueled expectations of increased demand for Paxlovid, which has shown an 89% risk reduction in outpatients.

Pfizer has filed Paxlovid for an FDA emergency use authorization and has signed a contract to provide 10 million courses to the U.S. government by 2022 for $5.29 billion.

Meanwhile, Pfizer is investing up to $1 billion to support the manufacturing and distribution of the COVID drug, including potentially signing on contract manufacturers, the company has said. It isn’t immediately clear whether the extra courses will come from Pfizer’s own facilities or external help.

The emergence of the new coronavirus variant, omicron, stoked concerns of the power of existing vaccines and therapeutics. Despite those worries, Paxlovid will likely still be effective, Bourla said.

“The good news is when it comes to our treatment, it was designed with that in mind, it was designed with the fact that most mutations are coming in the spikes,” Bourla said on CNBC’s “Squawk Box.”

The SARS-CoV-2 coronavirus behind COVID-19 uses the spike protein on its surface to infect healthy cells. Paxlovid is a protease inhibitor that’s designed to block an enzyme that the virus needs to replicate.

With molnupiravir’s efficacy slump and Roche’s retreat from its Atea Pharmaceuticals-partnered COVID pill program, Pfizer’s now looks to be the king in oral COVID treatment.

Before Merck’s data update and Pfizer’s capacity increase, SVB Leerink analyst Geoffrey Porges projected Paxlovid could contribute $24.2 billion to Pfizer’s top-line in 2022 alone. Also thanks to an estimated $29.7 billion from BioNTech-shared COVID vaccine Comirnaty, Pfizer’s total revenue next year could exceed $100 billion, Porges said in an investor note last week.

by Angus Liu

Source: fiercepharma.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).